Your browser doesn't support javascript.
loading
The genetic control of immunity to Plasmodium infection.
Grant, Audrey V; Roussilhon, Christian; Paul, Richard; Sakuntabhai, Anavaj.
Afiliação
  • Grant AV; Unité de la Génétique Fonctionnelle des Maladies Infectieuses, Institut Pasteur, Paris, France. audrey.grant@pasteur.fr.
  • Roussilhon C; Centre National de la Recherche Scientifique, URA3012, Paris, France. audrey.grant@pasteur.fr.
  • Paul R; Unité de la Génétique Fonctionnelle des Maladies Infectieuses, Institut Pasteur, Paris, France. roussilo@pasteur.fr.
  • Sakuntabhai A; Centre National de la Recherche Scientifique, URA3012, Paris, France. roussilo@pasteur.fr.
BMC Immunol ; 16: 14, 2015 Mar 26.
Article em En | MEDLINE | ID: mdl-25887595
ABSTRACT

BACKGROUND:

Malaria remains a major worldwide public health problem with ~207 million cases and ~627,000 deaths per year, mainly affecting children under five years of age in Africa. Recent efforts at elaborating a genetic architecture of malaria have focused on severe malaria, leading to the identification of two new genes and confirmation of previously known variants in HBB, ABO and G6PD, by exploring the whole human genome in genome-wide association (GWA) studies. Molecular pathways controlling phenotypes representing effectiveness of host immunity, notably parasitemia and IgG levels, are of particular interest given the current lack of an efficacious vaccine and the need for new treatment options.

RESULTS:

We propose a global causal framework of malaria phenotypes implicating progression from the initial infection with Plasmodium spp. to the development of the infection through liver and blood-stage multiplication cycles (parasitemia as a quantitative trait), to clinical malaria attack, and finally to severe malaria. Genetic polymorphism may control any of these stages, such that preceding stages act as mediators of subsequent stages. A biomarker of humoral immunity, IgG levels, can also be integrated into the framework, potentially mediating the impact of polymorphism by limiting parasitemia levels. Current knowledge of the genetic basis of parasitemia levels and IgG levels is reviewed through key examples including the hemoglobinopathies, showing that the protective effect of HBB variants on malaria clinical phenotypes may partially be mediated through parasitemia and cytophilic IgG levels. Another example is the IgG receptor FcγRIIa, encoded by FCGR2A, such that H131 homozygotes displayed higher IgG2 levels and were protective against high parasitemia and onset of malaria symptoms as shown in a causal diagram.

CONCLUSIONS:

We thus underline the value of parasitemia and IgG levels as phenotypes in the understanding of the human genetic architecture of malaria, and the need for applying GWA approaches to these phenotypes.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Malária Falciparum / Vacinas Antimaláricas / Malária Idioma: En Ano de publicação: 2015 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Malária Falciparum / Vacinas Antimaláricas / Malária Idioma: En Ano de publicação: 2015 Tipo de documento: Article País de afiliação: França